

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	18/LO/0513	230722	INFORAAA study	No					02/05/2017	21/06/2019	10/10/2018				C - Closed by sponsor	Sponsor
2	18/WA/0262	245893	CL140FSGS	No		4			29/03/2019	11/07/2019		07/07/2019	15/07/2019		C - Closed by sponsor	Sponsor
3	19/WM/0308	268333	Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof of concept study	No					17/06/2019	30/03/2020	29/10/2019					
4	19/WM/0097	246910	Project MURRAY: Feasibility Study	No					25/04/2019	22/07/2019					F - No patients seen	Neither
5	19/EM/0315	258745	P-VECT Study	No					16/06/2019	17/07/2019	18/11/2019				D - Sponsor Delays	Sponsor
6	19/NW/0519	266942	COPE- WEL	No		180			05/09/2019	05/09/2019	23/09/2019	29/01/2020	03/03/2020		D - Sponsor Delays	Sponsor
7	19/EE/0327	270157	inRange	No					22/10/2019	10/03/2020	13/02/2020					
8	19/NE/0110	257719	Precision medicine with zibotentan in microvascular angina (PRIZE)	No					07/10/2019	04/03/2020	04/12/2019					
9	18/ES/0119	245233	Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC)	No		101			07/11/2018	28/10/2019	09/11/2018	17/01/2020	06/02/2020		D - Sponsor Delays	Sponsor
10	18/NE/0052	234786	Avacopan in Patients with C3 Glomerulopathy	No					25/07/2019	17/12/2019	24/04/2018				C - Closed by sponsor	Sponsor
11	19/EM/0282	242364	ARTEMIS-IGAN	No					27/08/2019	24/02/2020						
12	19/SC/0566	265559	WAX	Yes	44076			194	21/02/2020	21/02/2020	02/12/2019					
13	18/SC/0472	234266	ProMPT-2	No		14			28/05/2019	14/02/2020	24/10/2018	11/02/2020	28/02/2020			
14	17/SC/0039	220282	MAGPIE	No					21/10/2019	12/02/2020	18/04/2017					
15	19/LO/0738	258589	TURING	No		21			28/10/2019	07/02/2020	14/06/2019		28/02/2020			
16	19/LO/1921	271139	Belantamab Mafodotin in newly diagnosed multiple myeloma	No		34			15/08/2019	05/02/2020	03/02/2020	25/02/2020	10/03/2020			
17	19/EM/0334	257450	Safety and Activity of Sparsentan in the Treatment of IgA Nephropathy	No					29/11/2019	08/01/2020	07/01/2020					
18	19/LO/1500	269558	BASIC Study PMCF	No		79			12/09/2019	30/10/2019	29/10/2019	05/12/2019	17/01/2020	21/01/2020	F - No patients seen	Neither
19	18/EE/0275	229033	(COMBIVAS)	Yes	44097	26	203	229	27/05/2019	07/02/2020		25/02/2020	04/03/2020		D - Sponsor Delays	Sponsor
20	19/EE/0286	255237	Mepolizumab for COPD Hospital Eosinophilic admissions Pragmatic trial1	No		10			13/09/2019	04/02/2020	12/12/2019	11/02/2020	14/02/2020		D - Sponsor Delays	Sponsor
21	19/EM/0063	253607	AMADEUS	Yes	43945	91	98	189	06/02/2019	18/10/2019	14/05/2019	09/01/2020	17/01/2020	22/01/2020	F - No patients seen	Neither
22	19/NW/0302	255677	VIP Study	Yes	43886	100	34	134	21/05/2019	14/10/2019	05/07/2019	29/10/2019	22/01/2020	23/01/2020	F - No patients seen	Neither
23	19/YH/0400	271539	DIAMOND Study	No					29/01/2020	29/01/2020	09/01/2020				E - Staff availability issues	NHS Provider
24	19/LO/0571	256756	Benralizumab Exacerbation Study	No		0			23/11/2018	08/10/2019	22/01/2020	08/10/2019	08/10/2019		F - No patients seen	Neither
25	18/NW/0031	230387	NET-02	No					10/03/2018	04/03/2020	08/02/2018	03/03/2020			D - Sponsor Delays	Sponsor
26	19/EM/0221	261147	Feasibility of low energy diet in HFpEF and type 2 diabetes	No		148			19/02/2019	01/10/2019		23/01/2020	26/02/2020	28/02/2020	F - No patients seen	Neither
27	19/YH/0229	266822	Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD	No		166			13/08/2019	13/09/2019	07/09/2019	29/01/2020	26/02/2020	02/03/2020	F - No patients seen	Neither
28	19/NE/0235	260081	Phase 3 Trial of Balixafortide in Patients with HER2 -ve Breast Cancer	No		120			25/02/2019	23/09/2019	13/01/2020	02/01/2020	21/01/2020	19/02/2020	D - Sponsor Delays	Sponsor
29	17/SC/0476	186573	MERIT	No		104			14/11/2018	06/09/2019	07/11/2017	04/10/2019	19/12/2019		F - No patients seen	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
30	18/NW/0765	250220	Testing a novel aid to diagnosis of peritonitis in clinic v1	Yes	44017	0	146	146	21/08/2018	10/02/2020	01/04/2019	07/02/2020	10/02/2020		I - Rare diseases	Neither
31	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	Yes	43771	88	61	149	05/06/2019	06/06/2019	26/07/2019	02/09/2019	02/09/2019	24/10/2019	D - Sponsor Delays	Sponsor
32	19/LO/0981	260202	IMMU-132-09	No		209			07/05/2019	20/08/2019	16/08/2019	10/03/2020	16/03/2020	20/03/2020	F - No patients seen	Neither
33	20/EM/0003	269023	SurfON	Yes	44077			182	27/09/2019	05/03/2020	14/02/2020				D - Sponsor Delays	Sponsor
34	19/LO/0553	257627	GALACTIC-1 Phase 2b study in idiopathic pulmonary fibrosis (IPF)	Yes	43850	69	91	160	13/08/2019	13/08/2019	24/09/2019	21/10/2019	21/10/2019	31/10/2019	F - No patients seen	Neither
35	18/LO/0555	237992	PROTECTOR	Yes	44049	78	342	420	13/06/2019	13/06/2019	19/04/2018	31/07/2019	30/08/2019	15/10/2019	F - No patients seen	Sponsor
36	19/YH/0093	255567	ATLAS Study	Yes	43790	98	129	227	03/09/2018	08/04/2019	04/06/2019	05/07/2019	15/07/2019	06/08/2019	D - Sponsor Delays	Sponsor
37	18/SC/0644	242136	AVENue	No		61			22/02/2019	29/08/2019	19/02/2019	18/11/2019	29/10/2019	11/12/2019	D - Sponsor Delays	Sponsor
38	17/EE/0327	224081	REDJUVENATE	No		21			07/02/2017	18/07/2019	20/11/2017	18/01/2018	08/08/2019		F - No patients seen	Neither
39	18/LO/0165	224726	POLEM	Yes	43801	26	146	172	22/05/2017	13/06/2019	09/05/2018	02/07/2019	09/07/2019	20/09/2019	D - Sponsor Delays	Sponsor
40	19/SW/0140	265506	A study of benralizumab in EGPA (also known as Churg-Strauss Syndrome)	Yes	43865	129	95	224	25/06/2019	25/06/2019	20/08/2019	22/10/2019	01/11/2019	01/11/2019	F - No patients seen	Neither
41	18/NE/0296	248487	CALIBRE Study	Yes	43789	0	149	149	11/09/2018	24/06/2019	19/10/2018	05/03/2019	24/06/2019	27/09/2019	F - No patients seen	Neither
42	19/EM/0057	257429	LEAP-006	Yes	43829	11	182	193	22/10/2018	20/06/2019	08/05/2019	17/06/2019	01/07/2019	19/09/2019	D - Sponsor Delays	Sponsor
43	19/LO/1024	263894	Pembrolizumab ? SBRT in Medically Inoperable Stage I/IIA NSCLC	No		56			13/03/2019	02/08/2019	26/07/2019	25/09/2019	27/09/2019	01/11/2019	D - Sponsor Delays	Sponsor
44	19/NW/0021	234848	BIOTIPRA Feasibility Trial	Yes	43858	3	187	190	07/03/2019	22/07/2019	06/03/2019	22/07/2019	25/07/2019	15/10/2019	D - Sponsor Delays	Sponsor
45	19/LO/0384	239240	MRI for Aortic Dissection to Visualise inflammation	No		118			02/10/2018	10/05/2019	03/05/2019	10/07/2019	05/09/2019	11/09/2019	F - No patients seen	Neither
46	19/NW/0181	260431	RELIEF	Yes	43741	137	31	168	03/04/2019	18/04/2019	14/06/2019	06/08/2019	02/09/2019	10/09/2019	F - No patients seen	Neither
47	19/SC/0021	249552	OPTIMAS Trial	Yes	43837	28	109	137	03/04/2019	23/08/2019	04/04/2019	06/09/2019	20/09/2019	08/11/2019	D - Sponsor Delays	Sponsor

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
48	19/WA/0325	266292	EASY-AS	No		67			13/08/2019	19/12/2019	02/12/2019	16/01/2020	24/02/2020	04/03/2020	F - No patients seen	Neither
49	19/SS/0067	260562	BSET-ConformableLe EndoVascular Aneurysm Repair (CLEVAR) registry v1.0	No		21			11/09/2019	23/12/2019	30/05/2019	09/01/2020	13/01/2020	05/03/2020	D - Sponsor Delays	Sponsor
50	16/NW/0621	206740	Pro2tect-Conversion	No		1			14/12/2018	01/04/2019	21/10/2016	20/03/2019	02/04/2019	11/06/2019	D - Sponsor Delays	Sponsor
51	19/EM/0027	256620	Tens-La	No		71			07/12/2018	15/04/2019	12/03/2019	25/06/2019	25/06/2019	25/06/2019	B - Suspended by sponsor	Sponsor
52	19/SW/0093	260867	BMS11073	No		45			03/10/2018	19/08/2019	17/06/2019	20/09/2019	03/10/2019	28/10/2019	D - Sponsor Delays	Sponsor
53	18/SC/0243	240684	ORION-4	Yes	43752	15	104	119	03/07/2018	17/06/2019	17/10/2018	25/06/2019	02/07/2019	22/08/2019	D - Sponsor Delays	Sponsor
54	18/LO/1290	249002	Hookipa H-100-002	No		60			12/01/2018	25/11/2019	06/11/2018	20/01/2020	24/01/2020	29/01/2020	D - Sponsor Delays	Sponsor
55	19/YH/0026	256695	A first in human phase I/II study of MRx-4DP0004 in asthma	Yes	43755	9	141	150	19/02/2019	20/05/2019	09/04/2019	16/05/2019	29/05/2019	24/07/2019	D - Sponsor Delays	Sponsor
56	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	Yes	43880	15	119	134	03/09/2019	08/10/2019	07/12/2018	21/10/2019	23/10/2019	09/12/2019	D - Sponsor Delays	Sponsor
57	18/YH/0322	226765	SUNRRISE	Yes	43664	36	30	66	18/12/2018	13/05/2019	26/10/2018	13/05/2019	18/06/2019	11/07/2019	D - Sponsor Delays	Sponsor
58	18/SS/0079	226923	PRECISION	No		22			08/02/2018	15/07/2019	20/08/2018	15/07/2019	06/08/2019	11/09/2019	D - Sponsor Delays	Sponsor
59	19/SC/0418	261435	The RESET study - version 1.0	Yes	43895	52	56	108	16/09/2019	18/11/2019	24/09/2019	07/01/2020	09/01/2020	14/01/2020		
60	19/YH/0269	259860	The "SIT and be FIT" study - Version 1.0	Yes	43832	52	31	83	11/09/2019	11/10/2019	09/09/2019	13/11/2019	02/12/2019	05/12/2019		
61	19/NW/0570	234906	Efficacy and safety of LNP023 compared with rituximab in IMN	No		0			22/03/2019	05/12/2019	28/10/2019	28/11/2019	05/12/2019	28/01/2020	F - No patients seen	Neither
62	19/YH/0049	258945	A Phase 1c Study of Single Dose MTPS9579A in Patients with Asthma	Yes	43774	50	97	147	04/02/2018	11/06/2019	30/05/2019	22/07/2019	31/07/2019	01/08/2019	F - No patients seen	Neither
63	19/EM/0112	259565	Proof of mechanism QAW039 (fevipirant) in eosinophilic COPD patients	No		46			25/03/2019	22/04/2019	21/05/2019	03/06/2019	07/06/2019	12/06/2019	C - Closed by sponsor	Sponsor
64	17/EM/0440	230556	DANTE (Duration of Anti-PD1 therapy for melanoma)	Yes	43738	42	112	154	05/02/2018	29/04/2019	18/01/2018	29/05/2019	10/06/2019	14/06/2019	C - Closed by sponsor	Sponsor
65	19/EM/0031	254100	USURP AF-study II	Yes	43718	44	117	161	03/10/2018	02/04/2019	14/02/2019	16/05/2019	16/05/2019	17/05/2019		
66	17/SC/0536	216069	COPELJA	Yes	43720	35	72	107	31/01/2019	28/05/2019	04/12/2017	24/05/2019	02/07/2019	10/07/2019		
67	18/EE/0099	239606	CL3-95005-006 SOLSTICE	Yes	43770	38	161	199	19/12/2018	16/04/2019	01/06/2018	13/05/2019	24/05/2019	29/05/2019		
68	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	Yes	43782	27	16	43	10/07/2019	01/10/2019	15/10/2018	03/10/2019	28/10/2019	13/11/2019	D - Sponsor Delays, F - No	Neither
69	17/LO/1875	219487	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	Yes	43843	28	47	75	05/04/2017	30/10/2019	08/01/2018	05/11/2019	27/11/2019	11/12/2019	D - Sponsor Delays	Sponsor
70	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	Yes	43784	21	100	121	22/02/2018	17/07/2019	10/07/2017	19/08/2019	07/08/2019	23/08/2019	D - Sponsor Delays	Sponsor
71	19/LO/0343	255538	The PRECISE study	Yes	43872	36	69	105	13/08/2019	29/10/2019	12/08/2019	23/10/2019	04/12/2019	05/12/2019		
72	19/LO/0966	262945	Provention Bio's T1D Trial Evaluating C-Peptide with Teplizumab	No		2			05/08/2019	04/02/2020		05/11/2019	06/02/2020	11/03/2020	E - Staff availability issues	NHS Provider
73	19/YH/0094	256470	Protocol 18-513 Andexanet ICH	No		20			30/04/2019	04/07/2019	19/06/2019	27/06/2019	24/07/2019	09/08/2019	D - Sponsor Delays	Sponsor
74	19/SC/0151	253737	SMARTHEART Validation Study	No		35			13/11/2018	25/06/2019	17/05/2019	24/07/2019	30/07/2019	30/07/2019		
75	18/EM/0406	250403	The EURO-SHOCK Trial version 1	Yes	43899	27	130	157	03/10/2018	04/10/2019	04/03/2019	30/10/2019	31/10/2019	05/11/2019		
76	19/SC/0107	237804	ANICCA-Class II	No		28			14/02/2018	17/10/2019	05/07/2019	01/11/2019	14/11/2019	18/11/2019		
77	18/EE/0197	246434	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	Yes	43661	18	56	74	20/11/2018	02/05/2019	10/08/2018	23/04/2019	20/05/2019	03/06/2019	D - Sponsor Delays	Sponsor
78	19/LO/0855	260338	NKTR-214 Phase II urothelial cancer with low PD-L1 expression Study	Yes	43857	4	125	129	13/02/2019	20/09/2019	27/06/2019	11/09/2019	24/09/2019	21/10/2019	D - Sponsor Delays	Sponsor
79	16/WS/0114	200445	CHIL 5253	Yes	43766	14	76	90	08/05/2019	30/07/2019	27/09/2016	12/08/2019	13/08/2019	28/08/2019	D - Sponsor Delays	Sponsor
80	19/EE/0014	256539	IXchange	No		26			01/06/2018	08/05/2019	02/05/2019	21/05/2019	03/06/2019	05/06/2019	I - Rare diseases	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
81	19/EM/0201	261499	Diagnostic pathways for patients with chronic breathlessness.	Yes	43774	27	62	89	22/03/2019	08/08/2019	08/09/2019	19/07/2019	04/09/2019	05/09/2019		
82	19/EE/0200	265253	Investigating tirzepatide versus semaglutide in Type 2 Diabetes	Yes	43801	28	62	90	22/07/2019	03/09/2019	29/07/2019	30/09/2019	01/10/2019	01/10/2019		
83	19/EM/0258	266702	Fluids Exclusively Enteral from Day 1 (FEED1)	Yes	43796	27	7	34	10/09/2019	24/10/2019	13/09/2019	04/11/2019	20/11/2019	21/11/2019		
84	19/LO/0128	234820	Iron and Muscle	Yes	43691	5	30	35	16/01/2019	10/07/2019	07/03/2019	07/03/2019	15/07/2019	06/08/2019	D - Sponsor Delays	Sponsor
85	19/SW/0041	260477	Pembrolizumab + Lenvatinib verses Docetaxel in 2L+ NSCLC (LEAP-008)	Yes	43787	21	140	161	19/12/2018	10/06/2019	02/04/2019	21/06/2019	01/07/2019	05/07/2019		
86	19/NW/0158	259931	Surgery or Cast for Injuries of the Epicondyle in Children's Elbows	Yes	43648	20	5	25	13/03/2019	07/06/2019	25/03/2019	11/06/2019	27/06/2019	01/07/2019		
87	15/WA/0392	169633	SCOPE 2	Yes	43795	16	139	155	13/04/2018	24/06/2019	15/06/2016	23/05/2019	10/07/2019	17/07/2019		
88	18/WA/0199	108978	Azithromycin Therapy for Chronic Lung Disease of Prematurity	Yes	43747	21	2	23	19/06/2018	16/09/2019	29/06/2018	17/09/2019	07/10/2019	08/10/2019		
89	19/EM/0101	260487	SCENIC Trial	Yes	43690	0	63	63	15/01/2019	11/06/2019	20/05/2019	06/06/2019	11/06/2019	03/07/2019	D - Sponsor Delays	Sponsor
90	18/LO/2033	252294	WILL - When to Induce Labour to Limit risk in pregnancy hypertension	Yes	43762	20	107	127	12/03/2019	19/06/2019	10/01/2019	05/07/2019	09/07/2019	10/07/2019		
91	18/LO/0543	242259	Phase I/IIa study to evaluate CCS1477 in advanced tumours v1.0	Yes	43663	8	56	64	22/01/2019	14/05/2019	12/06/2018	17/05/2019	22/05/2019	03/06/2019	D - Sponsor Delays	Sponsor
92	19/YH/0097	261131	POSEIDON - ARC005	No		7			25/02/2019	13/06/2019	28/05/2019	17/06/2019	20/06/2019	03/07/2019	D - Sponsor Delays	Sponsor
93	19/WA/0028	233655	Brain TV - Clinical Investigation	Yes	43678	19	51	70	01/09/2018	23/05/2019	16/05/2019	06/06/2019	11/06/2019	11/06/2019		
94	19/SC/0221	259880	Phase I/IIa study to evaluate CCS1477 in haem. malignancies v1.0	Yes	43844	7	111	118	14/02/2019	18/09/2019	10/06/2019	24/09/2019	25/09/2019	04/10/2019		
95	19/WM/0178	262396	Multi-sited, mainstreaming of the term Snuby? to all types of births	Yes	43808	15	26	41	04/03/2019	29/10/2019	25/07/2019	29/10/2019	13/11/2019	13/11/2019		
96	19/LO/1270	261294	Cerclage after full dilatation caesarean section	Yes	43829	14	81	95	15/08/2019	26/09/2019	20/09/2019	19/09/2019	10/10/2019	10/10/2019		
97	20/EE/0101	281712	RECOVERY trial	Yes	43927	14	6	20	17/03/2020	17/03/2020	17/03/2020	13/03/2020	31/03/2020	31/03/2020		
98	19/EM/0299	265496	Real-time Remote Echo Mentoring	No		12			09/07/2019	27/02/2020	24/02/2020	20/08/2019	10/03/2020	10/03/2020	F - No patients seen	Neither
99	17/SC/0021	219693	NMES of the calf and thigh in OA knee - version 1.0	Yes	43630	5	37	42	21/03/2018	03/05/2019	09/03/2017	02/05/2019	08/05/2019	14/05/2019		
100	16/NW/0620	206738	Pro2tect-Correction	No		1			14/12/2018	01/04/2019	17/11/2016	20/03/2019	02/04/2019	11/04/2019		
101	19/EM/0290	263656	Home-based exercise in Renal Transplant patients: The ECSERT Study	Yes	43899	9	39	48	15/04/2019	21/01/2020	14/10/2019	23/01/2020	30/01/2020	30/01/2020		
102	20/NW/0168	281317	SARS-CoV-2 infection	Yes	43927	9	12	21	16/03/2020	16/03/2020	17/03/2020	24/03/2020	25/03/2020	25/03/2020	D - Sponsor Delays	Sponsor
103	18/SS/0120	233867	DENIM / DENdritic cell Immunotherapy for Mesothelioma	No		1			28/09/2017	08/10/2019	08/10/2019	09/10/2019	09/10/2019	15/10/2019		
104	19/EM/0060	260387	Study of cemdisiran in adult patients with IgAN	Yes	43853	0	182	182	22/01/2019	25/07/2019	04/02/2019	21/06/2019	25/07/2019	01/08/2019		
105	19/EM/0267	262581	SPACE FOR COPD maintenance	Yes	43789	0	41	41	11/11/2018	10/10/2019	10/10/2019	10/10/2019	10/10/2019	16/10/2019		
106	19/LO/0995	263661	Acceptability and tolerance study of Alfamino with HMOs	Yes	43801	5	68	73	26/07/2019	20/09/2019	24/06/2019	17/09/2019	25/09/2019	26/09/2019		
107	19/LO/0285	256948	A Multicenter Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)	Yes	43690	0	92	92	04/10/2018	13/05/2019	30/04/2019	07/05/2019	13/05/2019	16/05/2019		